WP 921

Drug Profile

WP 921

Alternative Names: TAT

Latest Information Update: 05 Dec 2007

Price : $50

At a glance

  • Originator Wakamoto
  • Developer Toyama Chemical; Wakamoto
  • Class Antihyperglycaemics
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic complications

Most Recent Events

  • 09 Feb 2000 No-Development-Reported for Diabetic complications in Japan (PO)
  • 12 Mar 1996 A preclinical study has been added to the Diabetes pharmacodynamics section
  • 12 Oct 1995 An in vivo study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top